Early CMC Strategy
Strategic guidance on developability, manufacturability, and risk mitigation to support efficient transition from discovery to early development.
Core Capabilities
Drug Product Development
Support across formulation design, process considerations, and early-stage development of complex therapeutic modalities.
Delivery Platform Evaluation
Assessment and selection of delivery technologies, including lipid nanoparticles and emerging systems, aligned with target product profiles.
Discovery to Development Transition
Bridging research and development through structured decision frameworks, enabling scalable and clinically viable product strategies.
News & Insights - UNDER CONSTRUCTION
Bridging Discovery and Early Development
Early decisions in formulation and delivery platform selection often define downstream success. A structured approach to transition can significantly reduce development risk.
Delivery Platforms: Fit-for-Purpose vs Platform Thinking
Platform technologies offer efficiency, but misalignment with target product profiles remains a common failure point in early-stage programs.
Early CMC Strategy as a Value Driver
Proactive integration of CMC considerations at the discovery stage can accelerate timelines and improve the probability of clinical and regulatory success.
Contact
For consulting inquiries, collaborations, or discussions related to drug product development, delivery platforms, or early CMC strategy, please reach out directly:
Design based on Editorial by HTML5 UP